Strides Pharma Science is currently trading at Rs. 391.75, up by 2.35 points or 0.60% from its previous closing of Rs. 389.40 on the BSE.
The scrip opened at Rs. 394.70 and has touched a high and low of Rs. 396.05 and Rs. 388.40 respectively. So far 372594 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.40 on 22-Jan-2019 and a 52 week low of Rs. 288.00 on 09-Oct-2019.
Last one week high and low of the scrip stood at Rs. 396.05 and Rs. 384.85 respectively. The current market cap of the company is Rs. 3516.74 crore.
The promoters holding in the company stood at 31.28%, while Institutions and Non-Institutions held 46.45% and 22.27% respectively.
Strides Pharma Science’s step down subsidiary -- Strides Pharma Inc. (SPI), has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its facility in Riviera Beach, Florida, US.
The EIR was issued as an outcome of the USFDA’s inspection of the facility in December 2019. This facility is one of the very few manufacturing facilities in the US with a soft gel capsule (SGC) manufacturing suite for formulations with containment needs.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1483.20 |
Dr. Reddys Lab | 5995.35 |
Cipla | 1357.05 |
Zydus Lifesciences | 961.30 |
Lupin | 1585.00 |
View more.. |